- Trials with a EudraCT protocol (7,054)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7,054 result(s) found for: Prior Placebo.
Displaying page 1 of 353.
EudraCT Number: 2019-001717-17 | Sponsor Protocol Number: P1901GF | Start Date*: 2019-10-23 | |||||||||||
Sponsor Name:Pohl-Boskamp GmbH & Co. KG | |||||||||||||
Full Title: A multi-centre, randomised, placebo-controlled, double-blind parallel-group trial to assess the efficacy and safety of SIA capsules in subjects with acute rhinosinusitis. | |||||||||||||
Medical condition: acute rhinosinusitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000103-20 | Sponsor Protocol Number: 202000638 | Start Date*: 2021-07-15 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa | ||
Medical condition: Genetic Epidermolysis Bullosa | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004575-74 | Sponsor Protocol Number: CAIN457FDE03 | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ... | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004169-41 | Sponsor Protocol Number: CQAB149B2329 | Start Date*: 2006-01-19 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 52-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d) in patients wi... | ||
Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-010739-42 | Sponsor Protocol Number: H6D-MC-LVID | Start Date*: 2009-10-01 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002192-19 | Sponsor Protocol Number: ISIS678354-CS5 | Start Date*: 2022-07-22 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia | ||||||||||||||||||
Medical condition: Severe hypertryglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000007-39 | Sponsor Protocol Number: N/A. | Start Date*: 2023-03-23 | |||||||||||
Sponsor Name:Aarhus University Hospital, Department of Endocrinology and Internal Medicine | |||||||||||||
Full Title: Bisphosphonate vs. Placebo Prior to Parathyroidectomy in Primary Hyperparathyroidisme: A Randomized, blinded Placebo-controlled Trial | |||||||||||||
Medical condition: Osteopenia i.e. bone mineral density T-score < -1 in patients with primary hyperparathyroidism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005030-73 | Sponsor Protocol Number: AVD111960 | Start Date*: 2009-11-11 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In Peopl... | |||||||||||||
Medical condition: - Incidence of CV outcomes compared to placebo for the TZD class as a whole, rosiglitazone (RSG), and pioglitazone (PIO) when added to the therapeutic regimen of a person with type 2 diabetes who h... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) CZ (Prematurely Ended) NL (Completed) DE (Completed) DK (Prematurely Ended) SK (Prematurely Ended) FR (Prematurely Ended) LV (Prematurely Ended) IE (Completed) IT (Prematurely Ended) FI (Completed) GB (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001954-91 | Sponsor Protocol Number: EFC15805 | Start Date*: 2020-06-04 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstr... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) LV (Completed) NL (Completed) LT (Completed) BG (Completed) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) PT (Completed) PL (Prematurely Ended) ES (Prematurely Ended) GR (Completed) BE (Completed) HU (Prematurely Ended) CZ (Completed) SK (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005710-12 | Sponsor Protocol Number: Ep_Li 001_2006 | Start Date*: 2007-09-28 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) | ||
Medical condition: Lipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated L... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-000594-81 | Sponsor Protocol Number: S65020 | Start Date*: 2021-05-07 |
Sponsor Name:University Hospitals Leuven (UZ Leuven) | ||
Full Title: The effect of corticotropin release hormone on duodenal markers and gastric sensorimotor function in healthy volunteers | ||
Medical condition: To assess the effect of the CRH on duodenal mast cell count, eosinophil count, immune activation, mucosal permeability and gastric sensorimotor function and gastrointestinal symptoms. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004545-32 | Sponsor Protocol Number: EP-002 | Start Date*: 2020-04-16 | |||||||||||
Sponsor Name:Empros Pharma AB | |||||||||||||
Full Title: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating th... | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002187-32 | Sponsor Protocol Number: DMSG03/14 | Start Date*: 2014-09-05 |
Sponsor Name:Danish Myeloma Study Group | ||
Full Title: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagno... | ||
Medical condition: multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-002306-39 | Sponsor Protocol Number: 156-03-236 | Start Date*: 2005-07-15 |
Sponsor Name:Otsuka Maryland Research Institute, Inc. | ||
Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure | ||
Medical condition: Subjects hospitalized with worsening congestive heart failure (CHF). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004055-37 | Sponsor Protocol Number: ALXN1830-WAI-201 | Start Date*: 2020-05-06 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | |||||||||||||
Medical condition: WAIHA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000506-34 | Sponsor Protocol Number: EMERA006 | Start Date*: 2019-02-04 |
Sponsor Name:NBMI Science Ltd. | ||
Full Title: EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear... | ||
Medical condition: PSP or MSA | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004206-25 | Sponsor Protocol Number: 1839IL/0711 | Start Date*: 2005-03-02 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAP... | ||
Medical condition: Non-Small Cell Lung Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000937-30 | Sponsor Protocol Number: ABX464-101 | Start Date*: 2017-09-29 | |||||||||||
Sponsor Name:ABIVAX | |||||||||||||
Full Title: A Phase IIa study to evaluate the safety and efficacy of ABX464 50 mg once daily versus Placebo in subjects with Moderate to Severe Active Ulcerative Colitis who have failed or are intolerant to im... | |||||||||||||
Medical condition: Moderate to severe Ulcerative Colitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) FR (Completed) DE (Completed) PL (Completed) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003526-25 | Sponsor Protocol Number: IC51-308 | Start Date*: 2005-10-26 |
Sponsor Name:Intercell AG | ||
Full Title: Safety and immunogenicity of concomitant vaccination with IC51 and Havrix 1440 in healthy subjects. A single-blind randomised, controlled phase 3 study. | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001771-36 | Sponsor Protocol Number: CHDR1755 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: Assessment of Neublastin-Induced Skin and Sensory Alterations and Headache in Healthy Subjects and Migraine Patients | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
